Pervasis Buyout Increases Shire’s Expertise In Regenerative Medicine
Specialty pharma says it will position ESRD candidate Vascugel for success, just as Shire is doing with Dermagraft, acquired in last year’s buyout of Advanced BioHealing.
Specialty pharma says it will position ESRD candidate Vascugel for success, just as Shire is doing with Dermagraft, acquired in last year’s buyout of Advanced BioHealing.